BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30247424)

  • 1. The Effect of Biologics on Postoperative Complications in Children With Inflammatory Bowel Disease and Bowel Resection.
    Mitsuya JB; Gonzalez R; Thomas R; El-Baba M
    J Pediatr Gastroenterol Nutr; 2019 Mar; 68(3):334-338. PubMed ID: 30247424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease.
    Lightner AL; Tse CS; Potter DD; Moir C
    J Pediatr Surg; 2018 Sep; 53(9):1706-1709. PubMed ID: 29111083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Review and Meta-Analysis: Preoperative Vedolizumab and Postoperative Complications in Patients with IBD.
    Moosvi Z; Duong JT; Bechtold ML; Nguyen DL
    South Med J; 2021 Feb; 114(2):98-105. PubMed ID: 33537791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease.
    Lightner AL; Raffals LE; Mathis KL; Cima RR; Tse CS; Pemberton JH; Dozois EJ; Loftus EV
    J Crohns Colitis; 2017 Feb; 11(2):185-190. PubMed ID: 27543504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case-matched Comparison of Postoperative Outcomes Following Surgery for Inflammatory Bowel Disease After Exposure to Vedolizumab vs Other Biologics.
    Novello M; Stocchi L; Steele SR; Holubar SD; Duraes LC; Kessler H; Shawki S; Hull LT
    J Crohns Colitis; 2020 Feb; 14(2):185-191. PubMed ID: 31328222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Fenster M; Ungaro RC; Hirten R; Gallinger Z; Cohen L; Atreja A; Mehandru S; Colombel JF; Cohen BL
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):257-258. PubMed ID: 30910602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative immunosuppression is not associated with increased postoperative complications following colectomy in children with colitis.
    Schaufler C; Lerer T; Campbell B; Weiss R; Cohen J; Sayej W; Hyams J
    J Pediatr Gastroenterol Nutr; 2012 Oct; 55(4):421-4. PubMed ID: 22395189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Preoperative Nutritional Status on the Incidence Rate of Surgical Complications in Patients With Inflammatory Bowel Disease With Vs Without Preoperative Biologic Therapy: A Case-Control Study.
    Yamamoto T; Shimoyama T; Umegae S; Kotze PG
    Clin Transl Gastroenterol; 2019 Jun; 10(6):e00050. PubMed ID: 31136361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of Last Preoperative Dose of Infliximab Does Not Increase Postoperative Complications in Inflammatory Bowel Disease Patients.
    Alsaleh A; Gaidos JK; Kang L; Kuemmerle JF
    Dig Dis Sci; 2016 Sep; 61(9):2602-7. PubMed ID: 27126205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles?
    Lightner AL; McKenna NP; Alsughayer A; Harmsen WS; Taparra K; Parker ME; Raffals LE; Loftus EV
    Dis Colon Rectum; 2019 Nov; 62(11):1352-1362. PubMed ID: 31567927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative infliximab therapy does not increase morbidity and mortality after laparoscopic resection for inflammatory bowel disease.
    Krane MK; Allaix ME; Zoccali M; Umanskiy K; Rubin MA; Villa A; Hurst RD; Fichera A
    Dis Colon Rectum; 2013 Apr; 56(4):449-57. PubMed ID: 23478612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries.
    Hansen TM; Targownik LE; Karimuddin A; Leung Y
    Inflamm Bowel Dis; 2019 Sep; 25(10):1613-1620. PubMed ID: 30794289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
    Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
    Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
    Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does perioperative biological therapy increase 30-day post-operative complication rates in inflammatory bowel disease patients undergoing intra-abdominal surgery? A systematic review.
    Byrne LW; McKay D
    Surgeon; 2021 Oct; 19(5):e153-e167. PubMed ID: 34581275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease.
    Waterman M; Xu W; Dinani A; Steinhart AH; Croitoru K; Nguyen GC; McLeod RS; Greenberg GR; Cohen Z; Silverberg MS
    Gut; 2013 Mar; 62(3):387-94. PubMed ID: 22619367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of perioperative treatment with biologics in patients with inflammatory bowel disease undergoing bowel surgery: Experience from a large urban center.
    Schnitzler F; Tillack-Schreiber C; Szokodi D; Braun I; Tomelden J; Sohn M; Bader F; Waggershauser C; Ochsenkühn T
    PLoS One; 2024; 19(1):e0290887. PubMed ID: 38236926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safe and effective: anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis.
    Kiely CJ; Subramaniam K; Platten J; Pavli P
    Intern Med J; 2016 May; 46(5):616-9. PubMed ID: 27170239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease.
    Wentworth BJ; Buerlein RCD; Tuskey AG; Overby MA; Smolkin ME; Behm BW
    Inflamm Bowel Dis; 2018 Aug; 24(9):2053-2061. PubMed ID: 29668917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.
    Tse CS; Loftus EV; Raffals LE; Gossard AA; Lightner AL
    Aliment Pharmacol Ther; 2018 Jul; 48(2):190-195. PubMed ID: 29808485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.